Canaccord Genuity Initiates Coverage On Tyra Biosciences with Buy Rating, Announces Price Target of $50

Benzinga Newsdesk www.benzinga.com Neutral 67.5%

Neg 0% Neu 67.5% Pos 0%

Canaccord Genuity analyst John Newman initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a Buy rating and announces Price Target of $50.